Search Results - "Pawar, Grishma"

Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting by Pawar, Grishma N, Parayath, Neha N, Nocera, Angela L, Bleier, Benjamin S, Amiji, Mansoor M

“…Delivering therapeutics across the blood-brain barrier (BBB) for treating central nervous system (CNS) diseases is one of the biggest challenges today as the…”
Get full text

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease? by O’Hara, Darren M., Pawar, Grishma, Kalia, Suneil K., Kalia, Lorraine V.

“…Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, characterized by prominent degeneration of dopaminergic neurons in the…”
Get full text

MicroRNA-34a Encapsulated in Hyaluronic Acid Nanoparticles Induces Epigenetic Changes with Altered Mitochondrial Bioenergetics and Apoptosis in Non-Small-Cell Lung Cancer Cells by Trivedi, Malav, Singh, Amit, Talekar, Meghna, Pawar, Grishma, Shah, Parin, Amiji, Mansoor

“…Therapies targeting epigenetic changes for cancer treatment are in Phase I/II trials; however, all of these target only nuclear DNA. Emerging evidence suggests…”
Get full text

Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson’s disease by Nim, Satra, O’Hara, Darren M., Corbi-Verge, Carles, Perez-Riba, Albert, Fujisawa, Kazuko, Kapadia, Minesh, Chau, Hien, Albanese, Federica, Pawar, Grishma, De Snoo, Mitchell L., Ngana, Sophie G., Kim, Jisun, El-Agnaf, Omar M. A., Rennella, Enrico, Kay, Lewis E., Kalia, Suneil K., Kalia, Lorraine V., Kim, Philip M.

“…Accumulation of α-synuclein into toxic oligomers or fibrils is implicated in dopaminergic neurodegeneration in Parkinson’s disease. Here we performed a…”
Get full text

Reduction of alpha-synuclein oligomers in preclinical models of Parkinson’s disease by electrical stimulation in vitro and deep brain stimulation in vivo by Lee, Eun Jung, Aguirre-Padilla, David Hernán, Fomenko, Anton, Pawar, Grishma, Kapadia, Minesh, George, Jimmy, Lozano, Andres M., Hamani, Clement, Kalia, Lorraine V., Kalia, Suneil K.

“…Deep brain stimulation (DBS) has been widely used to manage debilitating neurological symptoms in movement disorders such as Parkinson's disease (PD). Despite…”
Get full text

Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting by Pawar, Grishma, Parayath, Neha N, Sharma, Aditya A, Coito, Carlos, Khorkova, Olga, Hsiao, Jane, Curry, William T, Amiji, Mansoor M, Bleier, Benjamin S

“…The most significant obstacle in the treatment of neurological disorders is the blood-brain barrier (BBB), which prevents 98% of all potential…”
Get full text

Small molecule inhibitors of α-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans by Chen, Kevin S, Menezes, Krystal, Rodgers, Jarlath B, O'Hara, Darren M, Tran, Nhat, Fujisawa, Kazuko, Ishikura, Seiya, Khodaei, Shahin, Chau, Hien, Cranston, Anna, Kapadia, Minesh, Pawar, Grishma, Ping, Susan, Krizus, Aldis, Lacoste, Alix, Spangler, Scott, Visanji, Naomi P, Marras, Connie, Majbour, Nour K, El-Agnaf, Omar M A, Lozano, Andres M, Culotti, Joseph, Suo, Satoshi, Ryu, William S, Kalia, Suneil K, Kalia, Lorraine V

“…Parkinson's disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by α-synuclein oligomers. There is an…”
Get full text

CNS Delivery and Anti-Inflammatory Effects of Intranasally Administered Cyclosporine-A in Cationic Nanoformulations by Yadav, Sunita, Pawar, Grishma, Kulkarni, Praveen, Ferris, Craig, Amiji, Mansoor

“…The main objective of this study was to develop and evaluate the CNS delivery efficiency, distribution, therapeutic efficacy, and safety of cyclosporine A…”
Get more information

Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain by Padmakumar, Smrithi, Jones, Gregory, Pawar, Grishma, Khorkova, Olga, Hsiao, Jane, Kim, Jonghan, Amiji, Mansoor M., Bleier, Benjamin S.

“…The limitations of central nervous system (CNS) drug delivery conferred by the blood-brain barrier (BBB) have been a significant obstacle in the development of…”
Get full text

Small molecule inhibitors of [alpha]-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans by Chen, Kevin S, Menezes, Krystal, Rodgers, Jarlath B, O'Hara, Darren M, Tran, Nhat, Fujisawa, Kazuko, Ishikura, Seiya, Khodaei, Shahin, Chau, Hien, Cranston, Anna, Kapadia, Minesh, Pawar, Grishma, Ping, Susan, Krizus, Aldis, Lacoste, Alix, Spangler, Scott, Visanji, Naomi P, Marras, Connie, Majbour, Nour K, El-Agnaf, Omar M. A, Lozano, Andres M, Culotti, Joseph, Suo, Satoshi, Ryu, William S, Kalia, Suneil K, Kalia, Lorraine V

“…Background Parkinson's disease is a disabling neurodegenerative movement disorder characterized by dopaminergic neuron loss induced by [alpha]-synuclein…”
Get full text

Trans-nasal Mucosal Delivery of BDNF AntagoNAT Oligonucleotides Using Heterotopic Mucosal Engrafting for Parkinson's Disease by Pawar, Grishma N

“…Chronic neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s diseases (PD) are currently the major health care challenge around the…”
Get full text